[
  {
    "ts": null,
    "headline": "Merck (MRK) Builds Post-Keytruda Growth Plan, BMO Upgrades to Outperform",
    "summary": "Merck & Co. Inc. (NYSE:MRK) ranks among the most active blue chip stocks to buy now. With a raised price target of $130 per share, BMO Capital Markets upgraded Merck & Co. Inc. (NYSE:MRK) to Outperform on December 18, stating that the pharmaceutical company is working on a portfolio that can continue growth beyond the […]",
    "url": "https://finnhub.io/api/news?id=454377de9ef163536f1e10ddcc3f38ba4474385670decdb6b9f1463f978487f5",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768938385,
      "headline": "Merck (MRK) Builds Post-Keytruda Growth Plan, BMO Upgrades to Outperform",
      "id": 138189500,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Merck & Co. Inc. (NYSE:MRK) ranks among the most active blue chip stocks to buy now. With a raised price target of $130 per share, BMO Capital Markets upgraded Merck & Co. Inc. (NYSE:MRK) to Outperform on December 18, stating that the pharmaceutical company is working on a portfolio that can continue growth beyond the […]",
      "url": "https://finnhub.io/api/news?id=454377de9ef163536f1e10ddcc3f38ba4474385670decdb6b9f1463f978487f5"
    }
  },
  {
    "ts": null,
    "headline": "Is Merck’s Guardant Liquid Biopsy Alliance Reshaping the Investment Case for MRK?",
    "summary": "Guardant Health recently announced a multi-year collaboration with Merck to use its Guardant Infinity Smart liquid and tissue biopsy platform to support Merck’s global oncology clinical trials, potential companion diagnostics, and commercialization efforts across major markets. This tie-up highlights how Merck is leaning on advanced molecular diagnostics to strengthen clinical development and personalize cancer treatment decisions across its pipeline. Next, we’ll examine how this deepening...",
    "url": "https://finnhub.io/api/news?id=184938719ce4e6ef4afedcf3f0c1e3cef4a693114f03fe34072dd542c0421472",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768918378,
      "headline": "Is Merck’s Guardant Liquid Biopsy Alliance Reshaping the Investment Case for MRK?",
      "id": 138187490,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Guardant Health recently announced a multi-year collaboration with Merck to use its Guardant Infinity Smart liquid and tissue biopsy platform to support Merck’s global oncology clinical trials, potential companion diagnostics, and commercialization efforts across major markets. This tie-up highlights how Merck is leaning on advanced molecular diagnostics to strengthen clinical development and personalize cancer treatment decisions across its pipeline. Next, we’ll examine how this deepening...",
      "url": "https://finnhub.io/api/news?id=184938719ce4e6ef4afedcf3f0c1e3cef4a693114f03fe34072dd542c0421472"
    }
  },
  {
    "ts": null,
    "headline": "Will Weak Gardasil Sales Continue to Ail MRK Revenues in Q4 Earnings?",
    "summary": "Gardasil's sharp sales slump in China and Japan puts Merck under pressure heading into Q4 earnings, with the vaccine's sales expected to stay under strain.",
    "url": "https://finnhub.io/api/news?id=6d30c95bde0debfaff21266ef7c58bd14236381b30c742795744200907f0c1da",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768917000,
      "headline": "Will Weak Gardasil Sales Continue to Ail MRK Revenues in Q4 Earnings?",
      "id": 138187491,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Gardasil's sharp sales slump in China and Japan puts Merck under pressure heading into Q4 earnings, with the vaccine's sales expected to stay under strain.",
      "url": "https://finnhub.io/api/news?id=6d30c95bde0debfaff21266ef7c58bd14236381b30c742795744200907f0c1da"
    }
  },
  {
    "ts": null,
    "headline": "LaunchDarkly Expands Leadership Team in Response to Accelerated Growth and AI Tailwinds",
    "summary": "Company nears $200M in ARR as demand for production-ready AI infrastructure stimulates global adoptionOAKLAND, Calif., Jan. 20, 2026 (GLOBE NEWSWIRE) -- LaunchDarkly, the comprehensive feature management platform, today announced the appointment of Cameron Etezadi as Chief Technology Officer and Robert O’Donovan as Chief Financial Officer, along with the return of Jonathan Nolen as SVP of Product. These additions to the executive team come as the company is nearing $200 million in annual recurri",
    "url": "https://finnhub.io/api/news?id=e9e59564268ec4e8b454e22255a1205f7e781d470f4f35abb9283562406c15e7",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768914000,
      "headline": "LaunchDarkly Expands Leadership Team in Response to Accelerated Growth and AI Tailwinds",
      "id": 138186468,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Company nears $200M in ARR as demand for production-ready AI infrastructure stimulates global adoptionOAKLAND, Calif., Jan. 20, 2026 (GLOBE NEWSWIRE) -- LaunchDarkly, the comprehensive feature management platform, today announced the appointment of Cameron Etezadi as Chief Technology Officer and Robert O’Donovan as Chief Financial Officer, along with the return of Jonathan Nolen as SVP of Product. These additions to the executive team come as the company is nearing $200 million in annual recurri",
      "url": "https://finnhub.io/api/news?id=e9e59564268ec4e8b454e22255a1205f7e781d470f4f35abb9283562406c15e7"
    }
  },
  {
    "ts": null,
    "headline": "CURE: Benefits And Caveats Of The Leveraged Healthcare ETF",
    "summary": "Direxion CURE ETF offers 3x daily healthcare exposureâlearn risks like volatility decay and drift, plus tactical trading tips using XLV/index signals.",
    "url": "https://finnhub.io/api/news?id=ca3612c5b4891b901620bb4fdb6c38f001242d9ac0824dccbf1890b2577a24b9",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768912790,
      "headline": "CURE: Benefits And Caveats Of The Leveraged Healthcare ETF",
      "id": 138188296,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1351287260/image_1351287260.jpg?io=getty-c-w1536",
      "related": "MRK",
      "source": "SeekingAlpha",
      "summary": "Direxion CURE ETF offers 3x daily healthcare exposureâlearn risks like volatility decay and drift, plus tactical trading tips using XLV/index signals.",
      "url": "https://finnhub.io/api/news?id=ca3612c5b4891b901620bb4fdb6c38f001242d9ac0824dccbf1890b2577a24b9"
    }
  },
  {
    "ts": null,
    "headline": "Drug pricing, patent losses and deals: Here's what pharma execs see ahead in the industry",
    "summary": "Big pharma is grappling with new drug pricing deals and roughly $300 billion in potential lost revenue from patent expirations of blockbuster drugs.",
    "url": "https://finnhub.io/api/news?id=a2b8109ab9f0a21a179e533bf84322fb5f4112fed535176f1f27dd22755ee9dc",
    "source": "CNBC",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768911513,
      "headline": "Drug pricing, patent losses and deals: Here's what pharma execs see ahead in the industry",
      "id": 138188129,
      "image": "https://image.cnbcfm.com/api/v1/image/108244385-1766176930135-gettyimages-2252075211-TRUMP_DRUG_PRICING.jpeg?v=1766176955&w=1920&h=1080",
      "related": "MRK",
      "source": "CNBC",
      "summary": "Big pharma is grappling with new drug pricing deals and roughly $300 billion in potential lost revenue from patent expirations of blockbuster drugs. ",
      "url": "https://finnhub.io/api/news?id=a2b8109ab9f0a21a179e533bf84322fb5f4112fed535176f1f27dd22755ee9dc"
    }
  },
  {
    "ts": null,
    "headline": "This Biotech Stock Surges 64%. The Big Pharma M&A Battle Is Heating Up.",
    "summary": "Investors expect a surge in deal activity in 2026 as drug makers look to replenish pipelines and capitalize on low interest rates.",
    "url": "https://finnhub.io/api/news?id=ed09b44ab08f281a4de088cbafeaab49cefc834f8df46627d296be0c707030c5",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768911000,
      "headline": "This Biotech Stock Surges 64%. The Big Pharma M&A Battle Is Heating Up.",
      "id": 138186420,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Investors expect a surge in deal activity in 2026 as drug makers look to replenish pipelines and capitalize on low interest rates.",
      "url": "https://finnhub.io/api/news?id=ed09b44ab08f281a4de088cbafeaab49cefc834f8df46627d296be0c707030c5"
    }
  },
  {
    "ts": null,
    "headline": "Moderna & Merck Announce 5-Year Data for Intismeran Autogene in Combination With KEYTRUDA(R) (pembrolizumab) Demonstrated Sustained Improvement in the Primary Endpoint of Recurrence-Free Survival in Patients With High-Risk Stage III/IV Melanoma Following Complete Resection",
    "summary": "At a median five-year pre-planned follow-up of the Phase 2b KEYNOTE-942/mRNA-4157-P201 study, intismeran autogene in combination with KEYTRUDA reduced the risk of recurrence or death by 49% (HR=0.510; [95% CI, 0.294-0.887]) compared to KEYTRUDA alone ...",
    "url": "https://finnhub.io/api/news?id=bc451509fa838b9994d3707b3cc1d826b4277dcf21798801071dc9498daa3177",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768906800,
      "headline": "Moderna & Merck Announce 5-Year Data for Intismeran Autogene in Combination With KEYTRUDA(R) (pembrolizumab) Demonstrated Sustained Improvement in the Primary Endpoint of Recurrence-Free Survival in Patients With High-Risk Stage III/IV Melanoma Following Complete Resection",
      "id": 138185701,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "At a median five-year pre-planned follow-up of the Phase 2b KEYNOTE-942/mRNA-4157-P201 study, intismeran autogene in combination with KEYTRUDA reduced the risk of recurrence or death by 49% (HR=0.510; [95% CI, 0.294-0.887]) compared to KEYTRUDA alone ...",
      "url": "https://finnhub.io/api/news?id=bc451509fa838b9994d3707b3cc1d826b4277dcf21798801071dc9498daa3177"
    }
  },
  {
    "ts": null,
    "headline": "Merck CEO on US Business, Life Sciences Innovation",
    "summary": "Merck KGaA Chief Executive Officer Belen Garijo says the company will continue to collaborate with the US and deliver life sciences innovation to patients. She spoke to Bloomberg's Francine Lacqua on the sidelines of the 2026 World Economic Forum in Davos, Switzerland.",
    "url": "https://finnhub.io/api/news?id=330039872a46c7104fb96418aeeb491f4a10a23ff94e51e81a256f2801c2ac83",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768903403,
      "headline": "Merck CEO on US Business, Life Sciences Innovation",
      "id": 138185702,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Merck KGaA Chief Executive Officer Belen Garijo says the company will continue to collaborate with the US and deliver life sciences innovation to patients. She spoke to Bloomberg's Francine Lacqua on the sidelines of the 2026 World Economic Forum in Davos, Switzerland.",
      "url": "https://finnhub.io/api/news?id=330039872a46c7104fb96418aeeb491f4a10a23ff94e51e81a256f2801c2ac83"
    }
  },
  {
    "ts": null,
    "headline": "Merck & Co., Inc. (MRK) Poised for Breakout After Strategic M&A and Pipeline Expansion",
    "summary": "We recently compiled a list of the Top 10 Oncology Stocks to Buy Now. Merck & Co., Inc. tops our list for being one of the best cancer stocks. TheFly reported on January 8 that Wolfe Research analyst Alexandria Hammond upgraded MRK to Outperform from Peer Perform with a $135 price target. The firm described […]",
    "url": "https://finnhub.io/api/news?id=be5c7db69122eef4e416d29c8ad201e9a3fbb48caf020af023bce2fce357ff9c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768903055,
      "headline": "Merck & Co., Inc. (MRK) Poised for Breakout After Strategic M&A and Pipeline Expansion",
      "id": 138185703,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "We recently compiled a list of the Top 10 Oncology Stocks to Buy Now. Merck & Co., Inc. tops our list for being one of the best cancer stocks. TheFly reported on January 8 that Wolfe Research analyst Alexandria Hammond upgraded MRK to Outperform from Peer Perform with a $135 price target. The firm described […]",
      "url": "https://finnhub.io/api/news?id=be5c7db69122eef4e416d29c8ad201e9a3fbb48caf020af023bce2fce357ff9c"
    }
  },
  {
    "ts": null,
    "headline": "Texas, N. Carolina, Ohio, Pennsylvania — where pharma manufacturing investments have surged",
    "summary": "Pledged projects have landed in a handful of hotspots while giving rise to potential new hubs across the U.S.",
    "url": "https://finnhub.io/api/news?id=29eb1b73de3a68aad76b4ce27ece84f3cb32f6b1356d04dcd510e0c438ca2f2b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768895656,
      "headline": "Texas, N. Carolina, Ohio, Pennsylvania — where pharma manufacturing investments have surged",
      "id": 138186415,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Pledged projects have landed in a handful of hotspots while giving rise to potential new hubs across the U.S.",
      "url": "https://finnhub.io/api/news?id=29eb1b73de3a68aad76b4ce27ece84f3cb32f6b1356d04dcd510e0c438ca2f2b"
    }
  },
  {
    "ts": null,
    "headline": "The Bull Case For Illumina (ILMN) Could Change Following Its Billion Cell Atlas Pharma Alliance",
    "summary": "Earlier in January 2026, Illumina announced the Billion Cell Atlas alliance with AstraZeneca, Merck, and Eli Lilly, alongside new AI‑enabled genomics and multiomics platforms that integrate CRISPR, single-cell sequencing, and cloud analytics to support drug discovery and precision medicine. This push into large-scale genomics datasets and multiomic software marks a shift toward data-driven services that could reshape how Illumina works with pharmaceutical partners across the drug development...",
    "url": "https://finnhub.io/api/news?id=d20e84e98bba094dc7b7621bd83937b07ee3b91361cccee898537fbfe250fdb1",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768889399,
      "headline": "The Bull Case For Illumina (ILMN) Could Change Following Its Billion Cell Atlas Pharma Alliance",
      "id": 138184366,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Earlier in January 2026, Illumina announced the Billion Cell Atlas alliance with AstraZeneca, Merck, and Eli Lilly, alongside new AI‑enabled genomics and multiomics platforms that integrate CRISPR, single-cell sequencing, and cloud analytics to support drug discovery and precision medicine. This push into large-scale genomics datasets and multiomic software marks a shift toward data-driven services that could reshape how Illumina works with pharmaceutical partners across the drug development...",
      "url": "https://finnhub.io/api/news?id=d20e84e98bba094dc7b7621bd83937b07ee3b91361cccee898537fbfe250fdb1"
    }
  }
]